Tyra Biosciences, Inc.
Tyra Biosciences (Nasdaq: TYRA) is a clinical-stage biotechnology company developing precision medicines for targeted oncology and genetically defined conditions, with a focus on fibroblast growth factor receptor (FGFR) biology. Its wholly owned pipeline consists of oral small-molecule candidates designed using its… From the company’s description.
In fiscal 2025, Tyra Biosciences, Inc. reported a net loss of $119.95M. Operations used $95.14M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tyra Biosciences, Inc. does
In the company’s own words
Tyra Biosciences (Nasdaq: TYRA) is a clinical-stage biotechnology company developing precision medicines for targeted oncology and genetically defined conditions, with a focus on fibroblast growth factor receptor (FGFR) biology. Its wholly owned pipeline consists of oral small-molecule candidates designed using its SNÅP drug-discovery platform. The lead candidate, dabogratinib, is being evaluated in Phase 2 trials for FGFR3-altered urothelial cancers and achondroplasia in children; other clinical programs include TYRA-430 for FGF19-positive cancers, including hepatocellular carcinoma, and TYRA-200 for FGFR2-driven cancers, initially intrahepatic cholangiocarcinoma. The company’s discovery efforts also include preclinical programs in FGFR biology and other targets. Tyra retains development and commercialization rights to its pipeline and reports its business as a single company, rather than through operating segments. Its candidates are investigational and are not described as marketed products. For the fiscal year ended December 31, 2025, the company is focused on research and development rather than commercial product sales. Its website is www.tyra.bio.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CARLSBAD, CA
- Fiscal year end
- December
- CIK
- 1863127
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tyra Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tyra Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tyra Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tyra Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tyra Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”